RecruitingPhase 1Phase 2NCT05026632
NPI-002 Intravitreal Implant for the Delay of Cataract Progression
Safety and Efficacy of NPI-002 Intravitreal Implant for the Delay of Cataract Progression in Patients Undergoing Vitrectomy
Sponsor
Nacuity Pharmaceuticals, Inc.
Enrollment
30 participants
Start Date
Jan 27, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
This study will examine the safety and efficacy NPI-002 intravitreal implants post vitrectomy.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Indicated for vitrectomy
- Natural Lens in place at time of vitrectomy
- Some cataract present as assessed pre-operatively
Exclusion Criteria11
- Previous intraocular surgery in study eye.
- Clear zonular weakness or defects / coloboma.
- Not on stable dose of medications for other conditions.
- Need for oral corticosteroids during study participation.
- Evidence or history of uveitis, or ocular ischemia.
- Current smoker
- Use of supplemental oxygen
- Evidence or history of proliferative diabetic retinopathy.
- Current lung disease (PU, COPD, Asthma) resulting in decreased oxygen saturation.
- Sensitivity to thiol compounds.
- Participation in another clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGNPI-002 Intravitreal Implant
Implant inserted during vitrectomy.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05026632
Related Trials
Post-refractive IOL Outcomes With Clareon TruPlus
NCT076102261 location
Visual and Patient Reported Outcomes With Clareon TruPlus
NCT076483551 location
Development of a Mobile Terminal-Based Intelligent Detection System for Multiple Anterior Segment Diseases of the Eye
NCT076349131 location
Capella Scientia Development Study
NCT069874744 locations
Multicentric Clinical Investigation to Assess Safety and Performance of Lux HighAdd IOL
NCT064468173 locations